hydroxyindoleacetic acid has been researched along with Nausea in 25 studies
(5-hydroxyindol-3-yl)acetic acid : A member of the class of indole-3-acetic acids that is indole-3-acetic acid substituted by a hydroxy group at C-5.
Nausea: An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We compared the efficacy and safety of ondansetron (GR 38032F), a selective antagonist of serotonin S3 receptors, with that of placebo in controlling the nausea and vomiting induced by cisplatin treatment in 28 patients with cancer." | 9.06 | Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. ( Cubeddu, LX; Finn, AL; Fuenmayor, NT; Hoffmann, IS, 1990) |
| "We investigated the association between fluvoxamine and nausea from various viewpoints." | 7.71 | Characteristics of fluvoxamine-induced nausea. ( Nakamura, J; Shinkai, K; Terao, T; Ueda, N; Yoshimura, R, 2001) |
| "This study evaluated the relationship between prechemotherapy cortisol and 5-hydroxyindoleacetic acid (5-HIAA) excretion and chemotherapy-induced emesis." | 7.69 | 5-Hydroxyindoleacetic acid (5-HIAA) and cortisol excretion as predictors of chemotherapy-induced emesis. ( du Bois, A; Holy, R; Schaefer, W; Vach, W; Wechsel, U, 1996) |
| "The aim of this study was to evaluate the efficacy and safety of ondansetron, an antagonist of 5-hydroxytryptamine type 3 (serotonin 3) (5-HT3) receptors, in controlling nausea and vomiting induced by antineoplastic therapy in children affected by cancer." | 7.68 | Ondansetron, an antagonist of 5-HT3 receptors, in the treatment of antineoplastic drug-induced nausea and vomiting in children. ( Calabria, C; Casale, F; Di Tullio, M; Indolfi, P; Lampa, E; Lucarelli, C; Matera, MG; Rossi, F, 1993) |
| " The results may be summarized as follows: 1) The pharmacokinetic parameters of tropisetron revealed no significant change in the data between day 1 and day 5." | 6.68 | [Pharmacokinetic investigation of 5-day multiple dose of tropisetron capsule in patients who had received cisplatin and the usefulness of tropisetron capsule in the treatment of nausea and vomiting]. ( Akasaka, Y; Kimura, A; Nukariya, N; Ohtawa, M; Suminaga, M, 1995) |
| " PCPA (2 g 8 hourly for 2 or 3 days prior to cisplatin) reduced the spontaneous urinary excretion of 5-hydroxyindoleacetic acid (5-HIAA), inhibited the increase in urinary 5-HIAA induced by cisplatin and markedly attenuated the acute period of nausea and vomiting associated with the cytotoxic drug." | 5.08 | Treatment with para-chlorophenylalanine antagonises the emetic response and the serotonin-releasing actions of cisplatin in cancer patients. ( Alfieri, AB; Cubeddu, LX, 1995) |
| "We compared the efficacy and safety of ondansetron (GR 38032F), a selective antagonist of serotonin S3 receptors, with that of placebo in controlling the nausea and vomiting induced by cisplatin treatment in 28 patients with cancer." | 5.06 | Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. ( Cubeddu, LX; Finn, AL; Fuenmayor, NT; Hoffmann, IS, 1990) |
| " We theoretically evaluated the antiemetic effects of three 5-HT(3) receptor antagonists (granisetron, azasetron, palonosetron) on cisplatin-induced nausea and vomiting by estimating the time course of the 5-HT(3) receptor occupancy of serotonin." | 3.81 | Theoretical evaluation of antiemetic effects of 5-HT3 receptor antagonists for prevention of vomiting induced by cisplatin. ( Iwase, O; Nakajima, A; Nakamura, H; Okuyama, K; Takayanagi, R; Yamada, Y; Yokoyama, H; Yoshimoto, K, 2015) |
| "We investigated the association between fluvoxamine and nausea from various viewpoints." | 3.71 | Characteristics of fluvoxamine-induced nausea. ( Nakamura, J; Shinkai, K; Terao, T; Ueda, N; Yoshimura, R, 2001) |
| "Highly emetogenic drugs such as cisplatin induce an increase in the urinary 5-hydroxyindoleacetic acid (5-HIAA) level, the main metabolite of serotonin (5-HT), within the first 24 h following a single infusion, thus providing a possible cause for acute emesis and an explanation for the action of 5-HT3 antagonists." | 3.70 | Urinary 5-hydroxyindoleacetic acid (5-HIAA) excretion during multiple-day high-dose chemotherapy. ( Janes, RJ; Karjalainen, UP; Muhonen, T; Wiklund, T, 1998) |
| "This study evaluated the relationship between prechemotherapy cortisol and 5-hydroxyindoleacetic acid (5-HIAA) excretion and chemotherapy-induced emesis." | 3.69 | 5-Hydroxyindoleacetic acid (5-HIAA) and cortisol excretion as predictors of chemotherapy-induced emesis. ( du Bois, A; Holy, R; Schaefer, W; Vach, W; Wechsel, U, 1996) |
| "The aim of this study was to evaluate the efficacy and safety of ondansetron, an antagonist of 5-hydroxytryptamine type 3 (serotonin 3) (5-HT3) receptors, in controlling nausea and vomiting induced by antineoplastic therapy in children affected by cancer." | 3.68 | Ondansetron, an antagonist of 5-HT3 receptors, in the treatment of antineoplastic drug-induced nausea and vomiting in children. ( Calabria, C; Casale, F; Di Tullio, M; Indolfi, P; Lampa, E; Lucarelli, C; Matera, MG; Rossi, F, 1993) |
| " Comparisons between SP data stratified by cisplatin dosage and emetic phase were significantly different, P < 0." | 2.72 | 5-Hydroxyindoleacetic acid and substance P profiles in patients receiving emetogenic chemotherapy. ( Altaha, R; Auber, ML; Higa, GM; Hobbs, G; Kurian, S; Landreth, K; Piktel, D, 2006) |
| " The results may be summarized as follows: 1) The pharmacokinetic parameters of tropisetron revealed no significant change in the data between day 1 and day 5." | 2.68 | [Pharmacokinetic investigation of 5-day multiple dose of tropisetron capsule in patients who had received cisplatin and the usefulness of tropisetron capsule in the treatment of nausea and vomiting]. ( Akasaka, Y; Kimura, A; Nukariya, N; Ohtawa, M; Suminaga, M, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (36.00) | 18.7374 |
| 1990's | 10 (40.00) | 18.2507 |
| 2000's | 3 (12.00) | 29.6817 |
| 2010's | 3 (12.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nakamura, H | 2 |
| Yokoyama, H | 2 |
| Yoshimoto, K | 2 |
| Nakajima, A | 2 |
| Okuyama, K | 2 |
| Iwase, O | 2 |
| Yamada, Y | 2 |
| Takayanagi, R | 1 |
| Kulke, MH | 1 |
| Hörsch, D | 1 |
| Caplin, ME | 1 |
| Anthony, LB | 1 |
| Bergsland, E | 1 |
| Öberg, K | 1 |
| Welin, S | 1 |
| Warner, RR | 1 |
| Lombard-Bohas, C | 1 |
| Kunz, PL | 1 |
| Grande, E | 1 |
| Valle, JW | 1 |
| Fleming, D | 1 |
| Lapuerta, P | 1 |
| Banks, P | 1 |
| Jackson, S | 1 |
| Zambrowicz, B | 1 |
| Sands, AT | 1 |
| Pavel, M | 1 |
| Higa, GM | 1 |
| Auber, ML | 1 |
| Altaha, R | 1 |
| Piktel, D | 1 |
| Kurian, S | 1 |
| Hobbs, G | 1 |
| Landreth, K | 1 |
| Hartvig, P | 1 |
| Murakawa, M | 1 |
| Adachi, T | 1 |
| Nakao, S | 1 |
| Seo, N | 1 |
| Shingu, K | 1 |
| Mori, K | 1 |
| Alfieri, AB | 1 |
| Cubeddu, LX | 3 |
| Suminaga, M | 1 |
| Akasaka, Y | 1 |
| Nukariya, N | 1 |
| Kimura, A | 1 |
| Ohtawa, M | 1 |
| Wilder-Smith, OH | 1 |
| Borgeat, A | 1 |
| Chappuis, P | 1 |
| Fathi, M | 1 |
| Forni, M | 1 |
| Matera, MG | 1 |
| Di Tullio, M | 1 |
| Lucarelli, C | 1 |
| Casale, F | 1 |
| Calabria, C | 1 |
| Lampa, E | 1 |
| Indolfi, P | 1 |
| Rossi, F | 1 |
| du Bois, A | 1 |
| Vach, W | 1 |
| Wechsel, U | 1 |
| Holy, R | 1 |
| Schaefer, W | 1 |
| Janes, RJ | 1 |
| Muhonen, T | 1 |
| Karjalainen, UP | 1 |
| Wiklund, T | 1 |
| Ueda, N | 1 |
| Yoshimura, R | 1 |
| Shinkai, K | 1 |
| Terao, T | 1 |
| Nakamura, J | 1 |
| Takahashi, S | 1 |
| Kondo, H | 1 |
| Kato, N | 1 |
| McLellan, DL | 1 |
| Chalmers, RJ | 1 |
| Johnson, RH | 1 |
| Hoffmann, IS | 2 |
| Fuenmayor, NT | 2 |
| Malave, JJ | 1 |
| Finn, AL | 1 |
| Cangiano, C | 1 |
| Ceci, F | 1 |
| Cairella, M | 1 |
| Cascino, A | 1 |
| Del Ben, M | 1 |
| Laviano, A | 1 |
| Muscaritoli, M | 1 |
| Rossi-Fanelli, F | 1 |
| Rinne, UK | 1 |
| Sonninen, V | 1 |
| Sirtola, T | 1 |
| Coppen, A | 1 |
| Metcalfe, M | 1 |
| Carroll, JD | 1 |
| Morris, JG | 1 |
| Zabrodin, GD | 1 |
| Martin, WR | 1 |
| Sloan, JW | 1 |
| Tandon, RN | 1 |
| Sur, BK | 1 |
| Nath, K | 1 |
| Tamarkin, NR | 1 |
| Goodwin, FK | 1 |
| Axelrod, J | 1 |
| Cremata, VY | 1 |
| Koe, BK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Ondansetron Premedication Trial in Juvenile Idiopathic Arthritis[NCT04169828] | 176 participants (Anticipated) | Interventional | 2019-08-02 | Recruiting | |||
| Effects of Daily Supplementation of 5-HTP on Body Composition, a Randomized Investigation[NCT05216406] | 65 participants (Actual) | Interventional | 2021-01-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
12 trials available for hydroxyindoleacetic acid and Nausea
| Article | Year |
|---|---|
Method for individualized evaluation of antiemetic effect induced by 5-HT3 receptor antagonist.
Topics: Aged; Antiemetics; Creatinine; Female; Granisetron; Humans; Hydroxyindoleacetic Acid; Intestine, Sma | 2013 |
Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome.
Topics: Aged; Antineoplastic Agents, Hormonal; Defecation; Diarrhea; Double-Blind Method; Female; gamma-Glut | 2017 |
5-Hydroxyindoleacetic acid and substance P profiles in patients receiving emetogenic chemotherapy.
Topics: Adult; Aged; Analysis of Variance; Antiemetics; Antineoplastic Agents; Biomarkers; Chromatography, H | 2006 |
Treatment with para-chlorophenylalanine antagonises the emetic response and the serotonin-releasing actions of cisplatin in cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fenclonine; Gastrointestin | 1995 |
[Pharmacokinetic investigation of 5-day multiple dose of tropisetron capsule in patients who had received cisplatin and the usefulness of tropisetron capsule in the treatment of nausea and vomiting].
Topics: Adult; Aged; Antiemetics; Capsules; Cisplatin; Drug Administration Schedule; Humans; Hydroxyindoleac | 1995 |
Clinical and pharmacological evaluation of the effects of piribedil in patients with parkinsonism.
Topics: Aged; Antiparkinson Agents; Chorea; Clinical Trials as Topic; Confusion; Dioxoles; Dopamine; Drug Ev | 1975 |
Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Cisplatin; Double-Blind Method; Female; Humans; Hydroxyindoleacetic Acid; | 1990 |
Effects of 5-hydroxytryptophan on eating behavior and adherence to dietary prescriptions in obese adult subjects.
Topics: 5-Hydroxytryptophan; Adult; Anorexia; Diet, Reducing; Dietary Carbohydrates; Feeding Behavior; Femal | 1991 |
Treatment of Parkinson's disease with L-DOPA and decarboxylase inhibitor.
Topics: Biopsy; Carboxy-Lyases; Clinical Trials as Topic; Dihydroxyphenylalanine; Drug Combinations; Drug Sy | 1972 |
Levodopa and L-tryptophan therapy in Parkinsonism.
Topics: Aged; Depression; Dihydroxyphenylalanine; Female; Gait; Homovanillic Acid; Humans; Hydroxyindoleacet | 1972 |
Effects of infused tryptamine in man.
Topics: Blood Pressure; Clinical Trials as Topic; Creatinine; Dopamine; Epinephrine; Hearing; Humans; Hydrog | 1970 |
Clinical and biochemical effects of fenclonine: a serotonin depletor.
Topics: Adult; Fatigue; Headache; Humans; Hydroxyindoleacetic Acid; Male; Nausea; Phenylalanine; Placebos; S | 1968 |
13 other studies available for hydroxyindoleacetic acid and Nausea
| Article | Year |
|---|---|
Theoretical evaluation of antiemetic effects of 5-HT3 receptor antagonists for prevention of vomiting induced by cisplatin.
Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cisplatin; Constipation; Creatinine; | 2015 |
Re: 5-Hydroxyindoleacetic acid and substance P profiles in patients receiving emetogenic chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Humans; Hydroxyindoleacetic Acid; Nausea; Serotonin 5-HT3 Recept | 2007 |
Activation of the cortical and medullary dopaminergic systems by nitrous oxide in rats: a possible neurochemical basis for psychotropic effects and postanesthetic nausea and vomiting.
Topics: Anesthesia; Animals; Biogenic Amines; Brain; Dihydroxyphenylalanine; Dopamine; Homovanillic Acid; Hy | 1994 |
Urinary serotonin metabolite excretion during cisplatin chemotherapy.
Topics: Adult; Aged; Cisplatin; Female; Humans; Hydroxyindoleacetic Acid; Middle Aged; Nausea; Serotonin; Ti | 1993 |
Ondansetron, an antagonist of 5-HT3 receptors, in the treatment of antineoplastic drug-induced nausea and vomiting in children.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Humans; Hydroxyindoleacetic | 1993 |
5-Hydroxyindoleacetic acid (5-HIAA) and cortisol excretion as predictors of chemotherapy-induced emesis.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Female; Humans; Hydrocortisone; Hydroxyindoleacetic | 1996 |
Urinary 5-hydroxyindoleacetic acid (5-HIAA) excretion during multiple-day high-dose chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans | 1998 |
Characteristics of fluvoxamine-induced nausea.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Benzamides; Depressive Disorder, Major; Dose-Response R | 2001 |
Effect of l-5-hydroxytryptophan on brain monoamine metabolism and evaluation of its clinical effect in depressed patients.
Topics: 5-Hydroxytryptophan; Adjustment Disorders; Adult; Aged; Blood Platelets; Brain; Depression; Female; | 1975 |
Changes in serotonin metabolism in cancer patients: its relationship to nausea and vomiting induced by chemotherapeutic drugs.
Topics: Adult; Analysis of Variance; Antineoplastic Agents; Blood Platelets; Cisplatin; Cyclophosphamide; Do | 1992 |
[The effect of reserpine on serotonin metabolism in patients with schizophrenia and reactive conditions].
Topics: Adjustment Disorders; Adult; Autonomic Nervous System; Blood Pressure; Blushing; Gastrointestinal Mo | 1974 |
Effect of reserpine injections in migrainous and normal control subjects, with estimations of urinary 5-hydroxyindoleacetic acid.
Topics: Adult; Headache; Humans; Hydroxyindoleacetic Acid; Injections, Subcutaneous; Male; Migraine Disorder | 1969 |
Rapid elevation of biogenic amine metabolites in human CSF following probenecid.
Topics: Administration, Oral; Affective Symptoms; Dihydroxyphenylalanine; Female; Headache; Humans; Hydroxyi | 1970 |